Filing Flows › Kenvue (KVUE) › Recalls, complaints & regulation
Kenvue (KVUE): recalls and EPA violations
Kenvue (KVUE) beyond its filings: 0 recalls in the last 12 months (1 in five years, 0 Class I); 1 EPA-regulated facility in violation, no penalties in five years.
Latest recalls
- 2025-11-05 · FDA drug · TYLENOL, Acetaminophen, Extra Strength, 24 Caplets, 500mg each, distributed by: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division, Fort Washi
EPA facilities in violation
| Facility (as registered) | City | Status | Penalties |
|---|---|---|---|
| KENVUE BRANDS LLC/WHITEMARSH TWP | Fort Washington, PA | Violation Identified | — |
Facilities in the EPA's ECHO register whose registered name matches the company's; a facility can belong to another business of the same name.
Kenvue's latest quarter
Kenvue, Q3 2026: revenue $3.9B (+3% year over year), operating margin 18.2%, net earnings $430M, operating cash flow $700M. The chart follows the revenue to costs, profit and cash.
Questions
Has Kenvue had any recalls?
1 recall on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.
Has Kenvue been fined by the EPA?
The 6 EPA-regulated facilities on file under its name drew no penalties in five years; 1 is in violation now.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.